News & Updates
Filter by Specialty:
Intranasal neuroEPO slows Alzheimer’s progression
An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.
Intranasal neuroEPO slows Alzheimer’s progression
04 Jan 2024
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
In the treatment of patients with acute ischaemic stroke, treatment with exenatide does not appear to have any beneficial effect on neurological function at 7 days but is safe and substantially decreases the frequency of hyperglycaemic events, without leading to hypoglycaemia, according to the results of the phase II TEXAIS trial.
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
12 Dec 2023
Light therapy associated with improved sleep and psychobehavioural symptoms in Alzheimer’s disease
A meta-analysis of 15 randomized controlled trials (RCTs) finds that light therapy significantly improves sleep efficiency, alleviates depression and reduces agitation in patients with Alzheimer’s disease (AD), as well as lessens caregiver burden.